BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for ...
Cue Biopharma (CUE) has entered into a definitive securities purchase agreement to raise approximately $50.0M in gross proceeds through a private placement with a group of accredited institutional ...
Shares of Cue Biopharma were higher after the company said it has entered into a $50 million private placement of common stock and pre-funded warrants with a group of accredited investors. Shares were ...
BOSTON, April 30, 2026 (GLOBE NEWSWIRE)-- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results